A remimazolam-propofol meta-analysis illustrates why a combined safety outcome needs to be unpacked before it is used in a clinical argument.
Fourteen randomized trials involving 2,883 adults were included in this gastrointestinal endoscopy meta-analysis. The primary outcome combined cardiorespiratory adverse events such as hypotension, respiratory depression or hypoxemia, and bradycardia.
The pooled relative risk for that composite was 0.34 with remimazolam compared with propofol, with a 95% confidence interval of 0.27–0.44. Sedation success was comparable. Between-study heterogeneity for the composite was moderate, with an I-squared value of 56%.
A reduction in a combined endpoint does not establish the same reduction for each component. Component frequency and clinical seriousness can differ. The result also does not establish that all remimazolam regimens or all high-risk patients share the pooled effect.
All but one trial were conducted in East Asia, and populations, dosing, and event definitions varied. Recovery and satisfaction findings were not uniform across every study. For evidentiary use, name the composite and identify which complication is actually at issue. A claim about hypoxemia alone requires the relevant respiratory evidence, not an unexplained substitution of the overall combined estimate.
Original analysis of the supplied journal article, identified as PMC12947952.